Accordingly, we observed that treatment of A549 lung cancer cells with an anti-IL-6 neutralizing antibody significantly reduced cell proliferation, as indicated by the 20.4% decrease in the number of cells in the cell count assays (Fig. 1c), suggesting that IL-6 production is associated with KRAS-mutant lung cancer cell proliferation. Here, KRAS is linked to lung carcinoma.